Certara Simcyp Group Awarded Two New Grants From U.S. FDA; Amount Not Disclosed
Portfolio Pulse from Benzinga Newsdesk
Certara Simcyp Group has been awarded two new grants from the U.S. FDA to further develop its biosimulation technology for drug development. The grants will support the automation of Virtual Bioequivalence (VBE) trial simulations and the development of a robust dermal PBPK model for topical formulations.
August 29, 2023 | 12:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Certara has received two new grants from the FDA, which will likely support the company's growth and innovation in biosimulation technology for drug development.
The grants from the FDA will likely enhance Certara's capabilities in biosimulation technology, potentially leading to more efficient and cost-effective drug development. This could increase the company's market share and profitability, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100